



Immune Design  
 Investor Relations Department  
 Immune Design Corp. Attn:  
 Accounts Payab  
 601 Gateway Blvd. Suite 250  
 South San Francisco, CA 94080  
 United States

Visit IR website [↗](#)  
 Sign-up for Email alerts [↗](#)

**NASDAQ: IMDZ**

Last Trade:	7.60
Trade Time:	4:00 PM ET May 24, 2017
Change:	0.20 <span style="color: green;">↑</span> (+2.703%)
Day Range	7.20 - 7.75
52-Week Range	4.50 - 14.21
Volume	128,226


Stock information is provided by eSignal,  
 stock charts provided by EDGAR Online.  
 Stock data is delayed approximately 20  
 minutes.

**Company Profile**

Immune Design is a clinical stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design's clinical programs are the product of its two synergistic discovery platforms: ZVex™ and GLAAS™.

... [\(more\)](#)

**Stock Performance**



**Press Releases** [\[ View all \]](#)

- May 17, 2017  
[New Clinical and Biomarker Data Validate Immune Design's Lead Programs and Discovery Platforms](#)
- May 17, 2017  
[Immune Design Reports First Quarter 2017 Financial Results and Provides Corporate Update](#)
- May 8, 2017  
[Immune Design to Report First Quarter 2017 Financial Results & Provide Corporate Update](#)
- Apr 20, 2017  
[Immune Design Announces Presentations at the 2017 ASCO Annual Meeting](#)
- Mar 7, 2017  
[Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update](#)

**Financials** [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Mar 7, 2017  
[Annual Report \(10-K\)](#)
- Apr 26, 2017  
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017  
[Quarterly Report \(10-Q\)](#)
- Nov 9, 2016  
[Quarterly Report \(10-Q\)](#)
- Aug 9, 2016  
[Quarterly Report \(10-Q\)](#)